Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921625 | 0.85 | TP53 (0.60) | TP53LMNAKMT2AMAPTTHRB | |
| SCHEMBL29979168 | 0.85 | ATM (0.55) | LMNAKMT2AATMGFER | |
| SCHEMBL2925305 | 0.85 | ATM (0.55) | LMNAKMT2AATMGFER | |
| SCHEMBL8853550 | 0.78 | HDAC1 (0.57) | TP53LMNAKMT2AMAPTTHRB | |
| SCHEMBL3174136 | 0.75 | CA9 (0.56) | LMNAKMT2A | |
| SCHEMBL5638460 | 0.75 | KMT2A (0.62) | TP53LMNAKMT2AMAPTTHRB | |
| SCHEMBL5507140 | 0.75 | HDAC1 (0.57) | TP53LMNAKMT2AMAPTTHRB | |
| SCHEMBL14128442 | 0.74 | MAOB (0.57) | LMNAATM | |
| SCHEMBL3328663 | 0.73 | HDAC1 (0.55) | TP53LMNAKMT2AMAPTTHRB | |
| SCHEMBL2586707 | 0.72 | PKM (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359908-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2007-08-22 | — | — | EP | disclosed |
| US-7205408-B2 | Quinolines and nitrogenated derivative thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents | SMITHKLINE BEECHAM, P.L.C. (GB) | 2007-04-17 | — | — | US | disclosed |
| US-20040138219-A1 | Quinolines and nitrogenated derivative therof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-15 | — | — | US | disclosed |
| EP-1359908-A1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002056882-A1 | QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138219-A1 | Quinolines and nitrogenated derivative therof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents | NCF1, TEAD1, TYMS | TP53 1717/4885LMNA 2504/4885KMT2A 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.